Payment overview · 2025
General Payments
$1,016.97
28 reported records · 7 companies
Healthcare provider profile · identity verified
Mohd Azfar Malik, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · SAINT LOUIS, MO · NPI 1942208715
Verified facts
What the public records show
CMS Open Payments records show Mohd Azfar Malik, M.D. received $1,016.97 in general payments during 2025 across 28 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 53.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Invega Sustenna, Lybalvi, Qelbree, Rexulti.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Auvelity by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Spravato by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Supernus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Qelbree as an associated drug or biological on 61278 records involving 18421 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qelbree by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $548.02 | 53.9% | 18 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $246.10 | 24.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $92.50 | 9.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $55.59 | 5.5% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.99 | 3.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.24 | 1.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.53 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,016.97 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $548.02 | 18 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $246.10 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $92.50 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $55.59 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $55.59 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $36.99 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $18.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 44 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 135 | exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Qelbree qelbree |
2025 | Qelbree | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
44 | 14 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
135 | 40 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
135 | 40 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SPRAVATO open payments reported associated product |
CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254 |
Spravato · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Supernus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | Qelbree open payments reported associated product |
CMS Open Payments — General Payments 61278 supporting records · 18421 recipient NPIs · example record 1244861775 |
Qelbree · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 310 | 88 |
| Quetiapine Fumarate | Quetiapine Fumarate | 292 | 102 |
| Gabapentin | Gabapentin | 276 | 87 |
| Olanzapine | Olanzapine | 187 | 54 |
| Clozapine | Clozapine | 185 | 22 |
| Lamotrigine | Lamotrigine | 168 | 65 |
| Bupropion Xl | Bupropion Hcl | 164 | 64 |
| Trazodone Hcl | Trazodone Hcl | 139 | 52 |
| Caplyta | Lumateperone Tosylate | 135 | 40 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 124 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 44 |
| Mirtazapine | Mirtazapine | 117 | 48 |
| Alprazolam | Alprazolam | 114 | 40 |
| Lithium Carbonate Er | Lithium Carbonate | 107 | 36 |
| Lurasidone Hcl | Lurasidone Hcl | 107 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 43 |
| Buspirone Hcl | Buspirone Hcl | 97 | 36 |
| Propranolol Hcl | Propranolol Hcl | 97 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 39 |
| Lorazepam | Lorazepam | 71 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 25 |
| Risperidone | Risperidone | 67 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 64 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 64 | 24 |
| Olanzapine Odt | Olanzapine | 62 | 26 |
| Divalproex Sodium Er | Divalproex Sodium | 57 | 23 |
| Sertraline Hcl | Sertraline Hcl | 55 | 18 |
| Aripiprazole | Aripiprazole | 54 | 24 |
| Topiramate | Topiramate | 53 | 12 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 52 | 18 |
| Trintellix | Vortioxetine Hydrobromide | 50 | 13 |
| Abilify Maintena | Aripiprazole | 47 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 47 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 47 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 11 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 44 | 14 |
| Divalproex Sodium | Divalproex Sodium | 42 | 13 |
| Doxepin Hcl | Doxepin Hcl | 39 | 15 |
| Asenapine Maleate | Asenapine Maleate | 38 | 17 |
| Spravato | Esketamine Hcl | 38 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 36 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 16 |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 33 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 14 |
| Modafinil | Modafinil | 32 | 12 |
| Lybalvi | Olanzapine/Samidorphan Malate | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | 12 |
| Ziprasidone Hcl | Ziprasidone Hcl | 30 | suppressed |
| Diazepam | Diazepam | 29 | 12 |
| Atomoxetine Hcl | Atomoxetine Hcl | 28 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 28 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 28 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | 14 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 28 | 11 |
| Lithium Carbonate | Lithium Carbonate | 28 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | 11 |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 19 | suppressed |
| Lamotrigine Er | Lamotrigine | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Ingrezza | Valbenazine Tosylate | 18 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Risperidone Er | Risperidone Microspheres | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Qelbree | Viloxazine Hcl | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Desvenlafaxine Er | Desvenlafaxine | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Clozapine Odt | Clozapine | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,016.97 · 28 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ARISTADA, Auvelity, CAPLYTA, INVEGA SUSTENNA, LYBALVI, NEUROSTAR TMS THERAPY SYSTEM, Qelbree, REXULTI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error